13250-83-4

Upstream product

• 13250-82-3 2-(thiophen-3-yl)-1,3-dioxolane 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1403578-37-9 C₂₄H₂₆O₇S₂ 
• 81975-31-7 Ethyl 4-p-toluidinothieno<3,2-c>pyridine-6-carboxylate 
• 1315574-38-9 ethyl 3-[3-(1,3-dioxolan-2-yl)-2-thienyl]-2-triphenylphosphoranylideneaminopropenoate 
• 272-14-0 thieno[3,2-c]pyridine 
• 91388-50-0 (E)-2-(2-ethoxycarbonyl-2-methylethenyl)-3-formylthiophene tosylhydrazone 
• 91388-49-7 (E)-2-(2-ethoxycarbonylethenyl)-3-formylthiophene tosylhydrazone 

Relevant academic research and scientific papers

Synthesis of the fused heterobicycles 5-pyridin-2-yl-thieno[3,2-b]pyridine, 6-pyridin-2-yl-thieno[2,3-b]pyridine and 6-pyridin-2-yl-thieno[3,2-c]pyridine

Three new pyridyl thienopyridines, 5-pyridin-2-yl-thieno[3,2-b]pyridine, 6-pyridin-2-yl-thieno[2,3-b]pyridine and 6-pyridin-2-yl-thieno[3,2-c]pyridine, have been synthesized, each through a different synthetic sequence. Overall yields ranged from 8% to 32%. Georg Thieme Verlag Stuttgart.

NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

The present invention provides a novel compound having a superior calcium antagonism, in particular, a neuron-selective calcium antagonism. Namely, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. In the formula, Ar indicates an optionally substituted 5- to 14-membered aromatic ring etc.; the ring A indicates any one ring selected from a piperazine, a homopiperazine, a piperidine and the like; the ring B indicates an optionally substituted C3-14 hydrocarbon ring etc.; E indicates a single bond, a group represented by the formula -CO-, etc.; X indicates a single bond, an oxygen atom etc.; R1 indicates a hydrogen atom, a halogen atom, a hydroxyl group etc.; and D1, D2, W1 and W2 are the same as or different from each other and each represents a single bond or an optionally substituted C1-6 alkylene chain.